GlassScriptPhysician profile
Craig Schneider
NPI 1033616289
$1,715.54
in general payments reported to CMS, 2019-2025
31 companies · $653 in 2025
The $653 reported for 2025 was more than what 79% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $225 · 2024: $837 · 2025: $653.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,716.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,715.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $206.82 | 2023-2025 | Lynparza, Enhertu |
| Novartis Pharmaceuticals Corporation | $186.46 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $148.21 | 2023-2025 | |
| Acrotech Biopharma INC. | $139.93 | 2024-2025 | Beleodaq |
| Janssen Biotech, INC. | $136.01 | 2024-2025 | Rybrevant |
| Novocure INC. | $129.11 | 2023-2025 | Optune Gio, Optune |
| Takeda Pharmaceuticals U.S.A., INC. | $85.96 | 2024-2025 | Alunbrig, Iclusig, Fruzaqla |
| Exelixis INC. | $50.23 | 2024 | Cabometyx |
| Incyte Corporation | $45.91 | 2024 | Jakafi |
| Servier Pharmaceuticals LLC | $43.73 | 2025 | |
| Astellas Pharma US INC | $43.14 | 2024 | Padcev, Xtandi |
| Regeneron Healthcare Solutions, INC. | $39.40 | 2024 | Libtayo |
| Progenics Pharmaceuticals, INC. | $39.15 | 2023-2024 | Pylarify |
| Merck Sharp & Dohme LLC | $37.58 | 2024-2025 | Keytruda, Welireg |
| Genentech USA, INC. | $36.35 | 2023-2025 | Tecentriq, Polivy, Phesgo |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $35.44 | 2023 | Tukysa, Adcetris |
| Geron Corporation | $33.19 | 2025 | Rytelo |
| Daiichi Sankyo INC. | $29.00 | 2023 | Injectafer |
| Pharmacosmos Therapeutics INC. | $27.83 | 2025 | Monoferric |
| Jazz Pharmaceuticals INC. | $27.44 | 2023-2024 | |
| Pfizer INC. | $26.46 | 2024 | |
| Siemens Medical Solutions USA, INC. | $20.80 | 2025 | Varian Ethos Treatment Planning, Eclipse Treatment Planning System For External Beam Radiation Therapy |
| Taiho Oncology, INC. | $19.02 | 2025 | |
| Coherus Oncology, INC. | $18.80 | 2024 | |
| Glaxosmithkline, LLC. | $17.95 | 2025 | Zejula |
| Cti Biopharma Corp. | $16.75 | 2023 | Vonjo |
| Foundation Medicine, INC. | $15.91 | 2023 | |
| Beigene USA, INC. | $15.55 | 2024 | Brukinsa |
| Syndax Pharmaceuticals, INC. | $15.32 | 2025 | Revuforj |
| Caris Mpi, INC. | $14.27 | 2025 | Mi Cancer Seek |
| Beone Medicines USA, INC. | $13.82 | 2025 | Brukinsa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Schneider listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.